Scientific Programme EMUC18, Amsterdam, 8-11 November Friday, 9 November

Transcription

1 Scientific Programme EMUC18, Amsterdam, 8-11 November 2018 Friday, 9 November 08:30-08:40 Welcome and introduction Medical oncologist Manuela Schmidinger, Vienna (AT) - ESMO Radiation oncologist Peter Hoskin, Northwood (GB) - ESTRO Urologist Hein Van Poppel, Leuven (BE) - EAU 08:40-10:30 Prostate cancer management: Implementation without good evidence? Urological researcher - Kerstin Junker, Homburg (DE) Urologist - James N Dow, Aberdeen (GB) Radiation oncologist - Bradley Pieters, Amsterdam (NL) 08:40-08:50 Functional imaging for recurrent disease Nuclear medicine - Stefano Fanti, Bologna (IT) 08:50-09:00 Digital GU pathology Pathologist - Rodolfo Montironi, Ancona (IT) 09:00-09:10 High tech radiotherapy Radiation oncologist - Alberto Bossi, Villejuif (FR) 09:10-09:20 Salvage surgery for recurrent disease Urologist - Steven Joniau, Leuven (BE) 09:20-09:30 Sequencing of novel therapies in urogenital malignancies Medical Oncologist - Sergio Bracarda, Terni (IT) Improving prediction of clinically signficant prostate cancer. The role of Tumour derived circulating endothelial cells Research Scientist - Sebastian Bhakdi, Bangkok (TH) 09: How to generate good evidence for 2025? Biostatistician - Laurence Collette, Brussels (BE) :30 Discussion Urologist - James N Dow, Aberdeen (GB) Coffee break and poster viewing 11:00-12:25 Controversies and contradictions in staging of prostate cancer Chairs: Pathologist - Thomas Gevaert, Leuven (BE) Urologist - Igle-Jan De Jong, Groningen (NL) 11:00-11:20 Predictive statistics applied to diagnosis Statistician - Daniel Sjoberg, New York (US) 11:20-12:25 Multidisciplinary case discussion Case presenter: Urologist Giorgio Gandaglia, Milan (IT) Pathologist - Thomas Gevaert, Leuven (BE) Nuclear medicine - Arturo Chiti, Rozzano (IT) Radiation oncologist - Berardino De Bari, Besancon (FR) Urologist - Alberto Briganti, Milan (IT)

2 Medical oncologist - Stephane Oudard, Paris (FR) Radiologist - Harriet Thoeny, Berne (CH) 12:25-12:45 Update on consensus meetings Chairs: Medical oncologist - Silke Gillessen, St. Gallen (CH) Pathologist - Antonio Lopez-Beltran, Lisbon (PT) Urologist - Jeroen Van Moorselaar, Amsterdam (NL) 12:25-12:35 Update on EAU Prostate Cancer Center consensus meeting Urologist - Peter Albers, Dusseldorf (DE) 12:35-12:45 ECCO-ERQCC Urologist - Maurizio Brausi, Modena (IT) Radiation oncologist - Peter Hoskin, Northwood (GB) 12:45-14:00 Lunch break and poster viewing 13:00-14:00 Industry session 14:00-15:30 Immunotherapy: Evolving paradigms in GU cancers Chairs: Pathologist - Maurizio Colecchia, Milan (IT) Urologist - Igle-Jan De Jong, Groningen (NL) Medical oncologist - Silke Gillessen, St. Gallen (CH) Radiation oncologist - Ananya Choudhury, Manchester (GB) 14:00-14:30 Immunotherapy for all patients as first line in kidney cancer? YES Medical oncologist - Laurence Albiges, Villejuif (FR) vs NO Medical oncologist - Manuela Schmidinger, Vienna (AT) 14:30-14:45 Discussion and questions from the audience 14:45-14:55 Non metastatic MIBCa: Which role for immunotherapy? Medical oncologist - Andrea Necchi, Milan (IT) 14:55-15:10 Metastatic MIBC: When should immunotherapy be used? Medical oncologist - Aristotelis Bamias, Athens (GR) 15:10-15:30 Discussion and questions from audience 15:30-16:00 Coffee break and poster viewing 16:00-17:30 Kidney cancer in the frail patient Chairs: Urologist - Axel Bex, Amsterdam (NL) Urological researcher - Kerstin Junker, Homburg (DE) Pathologist - Gladell Paner, Chicago (US) 16:00-16:20 How to identify the frail patient? Urologist - Umberto Capitanio, Milan (IT) 16:20-17:30 Multidisciplinary case discussion Clinical case by YAU members Urologist - Maria Carmen Mir Maresma, Valencia (ES) Medical oncologist - Joaquim Bellmunt, Boston (US) Nuclear medicine - Stefano Fanti, Bologna (IT) Radiation oncologist - Peter Hoskin, Northwood (GB) Urologist - Brunolf Lagerveld, Amsterdam (NL) Pathologist - Gladell Paner, Chicago (US) Radiologist - Harriet Thoeny, Berne (CH)

3 Saturday, 10 November 08:00-10:00 New trials update: What we need to know Chairs: Biostatistician - Laurence Collette, Brussels (BE) Surgical oncologist - Ganesh Palapattu, Ann Arbor (US) Radiation oncologist - Alberto Bossi, Villejuif (FR) 08:00-08:20 Early hormonal manipulation in M0 CRPC Speaker: Medical oncologist - Karim Fizazi, Villejuif (FR) Discussant: Urologist - Thomas Steuber, Hamburg (DE) 08:20-08:40 CARMENA trial Speaker: Urologist - Arnaud Mejean, Paris (FR) Discussant: Urologist - Axel Bex, Amsterdam (NL) 08:40-09:00 POUT trial Speaker: Clinical oncologist - Alison Birtle, Preston (GB) Discussant: Urologist - Evanguelos Xylinas, Paris (FR) 09:00-09:20 STAMPEDE trial Speaker: Radiation oncologist - Nicholas James, Birmingham (GB) Discussant: Urologist - Noel Clarke, Manchester (GB) 09:20-09:40 PRECISION trial Speaker: Urologist - Caroline Moore, London (GB) Discussant: Urologist - Georg Salomon, Hamburg (DE) 09:40-10:00 HORRAD trial Speaker: Urologist - George van Andel, Amsterdam (NL) Discussant: Radiation oncologist - Gert De Meerleer, Leuven (BE) 10:00-10:30 Coffee break and poster viewing 10:30-11:00 Report from new consensus projects Chairs: Radiation oncologist - Berardino de Bari, Besancon (FR) Urologist - Hein Van Poppel, Leuven (BE) 10: EAU-ESMO Bladder Cancer consensus report Urologist - Fred Witjes, Nijmegen (NL) 10:45-11:00 Highlights of Active Surveillance consensus meeting in PCa Urologist - Monique Roobol, Rotterdam (NL) 11:00-11:10 PIONEER session Chairs: Radiation oncologist - Berardino de Bari, Besancon (FR) Urologist - Hein Van Poppel, Leuven (BE) Urologist - James N Dow, Aberdeen (GB) 11:10-12:00 New developments in prostate cancer evaluation Chairs: Pathologist - Rodolfo Montironi, Ancona (IT) Radiologist - Harriet Thoeny, Berne (CH) Urologist - Jochen Walz, Marseille (FR) Radiation oncologist - Carl Salembier, Brussels (BE)

4 11:10-11:35 Everything in prostate cancer pathology you were afraid to ask Speaker: Pathologist - Jonathan I. Epstein, Baltimore (US) Discussant: Urologist - Alberto Briganti, Milan (IT) 11:35 12:00 Radiomics: Images are more than pictures Speaker: Radiation oncologist - Philippe Lambin, Maastricht (NL) Discussant: Urologist - Jochen Walz, Marseille (FR) 12:00-12:30 Oral presentation of the 6 best abstracts Urologist - Theo De Reijke, Amsterdam (NL) Radiation oncologist - Thomas Wiegel, Ulm (DE) Diagnostic Accuracy of Targeted Prostate Biopsies: A Prospective Trial Comparing Micro- Ultrasound with Multiparametric MRI for the Detection of Prostate Cancer Giovanni Lughezzani, Rozzano (IT) Single centre audit of implementation of a care pathway in penile cancer Joren Vanthoor, Genk (BE) Making a judgement on the potential curability of recurrent Renal Cell Carcinoma (RCC): Differences in global per protocol vs. investigator based assessment Christian Beisland, Bergen (NO) The 4 years NMIBC recurrence rates within a prospective, randomized-controlled clinical setting NBI versus standard TURBT diagnostic accuracy and long-term evidence-based oncologic outcome Bogdan Geavlete, Bucharest (RO) Cabozantinib versus everolimus in patients with advanced renal cell carcinoma from Europe and the rest of the world: subgroup analysis of the METEOR trial Manuela Schmidinger, Vienna (AT) Automated Gleason grading of prostate cancer via deep learning Christian Fankhauser, Zürich (CH) Announcement 3 best unmoderated posters Urologist - Theo De Reijke, Amsterdam (NL) Radiation oncologist - Thomas Wiegel, Ulm (DE) Late breaking abstract presentation Urologist - Theo De Reijke, Amsterdam (NL) Radiation oncologist - Thomas Wiegel, Ulm (DE) Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscleinvasive urothelial carcinoma of the bladder Bernadett Szabados, Munich (DE) 12:40-14:00 Lunch break and poster viewing 13:00-14:00 Industry session 14:00-16:00 BCG refractory disease: Is cystectomy avoidable? Chairs: Urologist - Marek Babjuk, Prague (CZ) Medical oncologist - Susanne Osanto, Leiden (NL) Radiation oncologist - Robert Huddart, Sutton (GB)

5 14:00-14:15 Mechanisms of action and of resistance to BCG Urologist - George Thalmann, Berne (CH) 14:15-14:30 Pathological variants and predictive markers of BCG response Pathologist - Antonio Lopez-Beltran, Lisbon (PT) 14:30-14:45 Modified BCG trial (SAKK) Urologist - Cyrill Rentsch, Basel (CH) 14:45-15:00 Immunotherapy in NMIBCa Urologist - Morgan Roupret, Paris (FR) 15: Gene therapy Urologist - Colin Dinney, Houston (US) 15:15-15:30 Discussion 15:30-16:00 Case presentation Urologist - Evanguelos Xylinas, Paris (FR) 16:00-16:30 Coffee break and poster viewing 16:30-17:30 Nightmare session: It could happen to you Chairs: Pathologist - Ferran Algaba, Barcelona (ES) Medical oncologist - Susanne Osanto, Leiden (NL) Urologist - Shahrokh Shariat, Vienna (AT) Radiation oncologist - Piet Ost, Ghent (BE) 16:30-16:45 The urologist s nightmare Urologist - Oliver Hakenberg, Rostock (DE) 16:45-17:00 The radiation oncologist s nightmare Radiation oncologist - Gert De Meerleer, Leuven (BE) 17:00-17:15 The medical oncologist s nightmare Clinical oncologist Susanne Osanto, Leiden (NL) 17:15-17:30 The pathologist s nightmare Pathologist - Ferran Algaba, Barcelona (ES)

6 Sunday, 11 November 08:30-08:45 Announcement 3 best unmoderated posters Radiologist - Raymond Oyen, Leuven (BE) Radiation oncologist - Bradley Pieters, Amsterdam (NL) Urologist - Michiel Sedelaar, Nijmegen (NL) 08:45-09:00 EAU Research Foundation Urologist - Anders Bjartell, Malmö (SE) 09: Current dilemmas in the management of metastatic prostate cancer Chairs: Urologist - Hein Van Poppel, Leuven (BE) Medical oncologist - Silke Gillessen, St. Gallen (CH) Radiation oncologist - Peter Hoskin, Northwood (GB) 09:00-09:15 Cross-talk between primary and metastatic sites Pathologist - Mark Rubin, New York (US) 09:15-09:30 Cell free DNA in blood: The best source for response prediction? Molecular biologist - Alexander Wyatt, Vancouver (CA) 09:30-09:45 Why some patients get only oligo-metastatic disease? Surgical oncologist - Ganesh Palapattu, Ann Arbor (US) 09:45-10:05 Metastasis directed therapy for oligo-metastatic recurrence YES Radiation oncologist - Piet Ost, Ghent (BE) vs NO Urologist - Philip Cornford, Liverpool (GB) 10:05-10:25 Selected patients with castration sensitive PCa only require ADT YES Medical oncologist - Stephane Oudard, Paris (FR) vs NO Urologist - Nicolas Mottet, Saint-Étienne (FR) 10:25-10:45 What is the optimal combination therapy? Abiraterone or docetaxel? Or both? Medical oncologist - Silke Gillessen, St. Gallen (CH) 10:45-11:05 Discussion 11:05-11:50 Take home messages 11:05-11:15 Pathologist - Rodolfo Montironi, Ancona (IT) 11:15-11:25 Radiation oncologist - Anne Kiltie, Oxford (GB) 11:25-11:35 Urologist - Evanguelos Xylinas, Paris (FR) 11:35-11:45 Radiologist - Raymond Oyen, Leuven (BE) 11:45-11:55 Medical oncologist - Laurence Albiges, Villejuif (FR) 11:55-12:00 Closing remarks Medical Oncologist - Aristotelis Bamias, Athens (GR) - ESMO Radiation oncologist - Peter Hoskin, Northwood (GB) - ESTRO Urologist - Hein Van Poppel, Leuven (BE) - EAU